<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04436419</url>
  </required_header>
  <id_info>
    <org_study_id>3573-I</org_study_id>
    <nct_id>NCT04436419</nct_id>
  </id_info>
  <brief_title>Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study</brief_title>
  <acronym>PPAR-NAPAS</acronym>
  <official_title>Immunometabolic Effects of Non-drug Strategies in the Clinical Management of Obesity: Translational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fauqué</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Polyclinique de Cannes (IPOCA)</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Polyclinique de Cannes (IPOCA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Forty women aged between 18 and 75 years-old with a BMI&gt; 30kg/m2 are recruited to participate&#xD;
      in the evaluation of their medical management. They participate in an 8-week protocol as part&#xD;
      of hospital medical treatment for weight loss at the Oxford Polyclinic in Cannes (IPOCA). The&#xD;
      effects of 2 independent variables will be studied: (1) an adapted physical activity program&#xD;
      and (2) nutritional supplementation with R-α-Lipoic acid (2x300mg/d) versus placebo&#xD;
      (double-blind). The volunteers are randomly assigned to the different groups: Placebo with or&#xD;
      without exercise groups and ALA with or without exercise groups. At the start of the protocol&#xD;
      (T0), at 4 weeks (T4) and at 8 weeks (T8), various measurements are carried out (physical&#xD;
      capacities, nutritional status, body composition, distribution of adipose mass by CT-scan). A&#xD;
      venous sample taken for all participants is done at T0, T4 and T8 to investigate the immune&#xD;
      profile of circulating T lymphocytes.&#xD;
&#xD;
      This project is part of a translational research project to assess current care and to&#xD;
      investigate the immunometabolic effects of a non-drug medical care of obesity (adapted&#xD;
      physical activities, nutritional supplementation with α-lipoic acid, quality of food intake).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obesity-related inflammation is central to the development of type 2 diabetes and potentiated&#xD;
      by advancing age, inactive behavior and sedentary lifestyle. Metabolism and immunity are&#xD;
      entangled in their respective effects: the pathways of inflammation are involved in&#xD;
      metabolism and the metabolic state plays a predominant role in immune function. Physical&#xD;
      activity and calorie restriction are first-line, non-drug strategies recommended in reducing&#xD;
      obesity and insulin resistance and then prevent type 2 diabetes. However, the impact of their&#xD;
      combined effects on circulating immune cells or those residing in adipose tissue and skeletal&#xD;
      muscle, remains insufficiently understood to allow a nutritional prescription (i.e., quality&#xD;
      of nutritional intake and efficient doses of physical activity) favorable to preventive&#xD;
      medical care, individualized, and effective. If the risk associated with an increase in&#xD;
      visceral fat mass is linked to a change in the pro/anti-inflammatory status, it is essential&#xD;
      to reduce this risk by acting on its cause, regardless of the weight loss. In a context of&#xD;
      low-grade inflammation, these effects could lead to an anti-inflammatory profile of T cells,&#xD;
      specifically regulatory T cells (Treg) whose metabolism is extremely &quot;flexible&quot; at the&#xD;
      periphery and into visceral adipose tissue (directly involved in inflammation of obesity).&#xD;
&#xD;
      ALA (Alpha-Lipoic Acid) is known to play a pivotal role in cellular redox status and energy&#xD;
      metabolism by modulating inflammatory and metabolic signaling pathways such as those of&#xD;
      NF-kB, JNK, PI3K/Akt, p38 MAPK, AMPK or PPARβ/δ. As ALA is a possible metabolic modulator, it&#xD;
      would affect the metabolism of T cells. And therefore ALA could be a complementary measure to&#xD;
      non-drug strategies by potentiating the correction of the inflammatory state linked to&#xD;
      obesity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2, 2018</start_date>
  <completion_date type="Actual">March 16, 2020</completion_date>
  <primary_completion_date type="Actual">February 28, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Variation in the prevalence of regulatory T cells from Peripheral Blood Mononuclear Cells (PBMCs) drawn from whole blood at the beginning (T0), mid-course (T4) and the end of the course (T8).</measure>
    <time_frame>Through study completion, an average of 2 months</time_frame>
    <description>Cells were gently washed twice and resuspended in PBS. Stained cell preparations were analyzed using a BD FACS Canto II flow cytometer. The staining and gating strategy were used for traited human PBMCs by utilizing CD3+, CD4+, CD25+ and FoxP3+ antibodies. We have discriminated CD3+CD4+ versus CD3+CD4-. Finally, at this stage CD25+FoxP3+ (Regulatory T cells) cells were gated as part of the CD3+CD4+ population.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>60% increasing in PPARβ/δ expression, estimated from the level of expression of its main target gene CPT1a, in human PBMC between the beginning (T0) and end of the course (T8).</measure>
    <time_frame>Through study completion, an average of 2 months</time_frame>
    <description>Total mRNA was extracted with Trizol reagent and the relative amount of CPT1a mRNA was calculated using the comparative ΔΔCT method after quantitative RT-PCR analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Improvement of Redox status by measuring GSH/GSSH ratio in human whole blood between the beginning (T0) and end of the course (T8).</measure>
    <time_frame>Through study completion, an average of 3 months</time_frame>
    <description>The GSH/GSSG Assay is designed to accurately measure total, reduced and oxidized glutathione in biological samples using an enzymatic method that utilizes Ellman's Reagent (DTNB) and glutathione reductase (GR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction of the area from visceral adipose tissue measured by computed-tomography scan between the beginning (T0) and end of the course (T8).</measure>
    <time_frame>Through study completion, an average of 1 months</time_frame>
    <description>A computed-tomography scan (CT-scan) which allowed to discriminate the area of subcutaneous adipose tissue from visceral fatty area (VFA) was calculated from x-ray performed at the third lumbar level. Visceral abdominal adipose tissue was estimated by subtracting total abdominal and subcutaneous adipose tissues areas.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Obesity</condition>
  <condition>Obesity, Abdominal</condition>
  <condition>Obesity, Visceral</condition>
  <condition>Female</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients benefited from a complete hospitalization including dietary monitoring (food intake was controlled in order to provide 30% less of their estimated daily energy expenditure) with a personalized food plan and an adapted physical activity program (5 sessions per week supervised by a graduated health physical activity coach), plus placebo administration (2x per day) apart from meal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program, plus R-ALA enantiomer administration (2x300mg per day) apart from meal.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alpha lipoic acid (plus full hospitalization)</intervention_name>
    <description>Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:&#xD;
Inclusion criteria: BMI&gt; 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1*04-03/06 polymorphisms; recent hospitalization (&lt;1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.&#xD;
Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.&#xD;
Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals.</description>
    <arm_group_label>ALA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)</intervention_name>
    <description>Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BMI&gt; 30; aged between 18 and 75 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and/or lactating women; not affiliated with social security; not mutual&#xD;
             health insurance; person deprived of liberty; participation in clinical research in&#xD;
             the last 6 months&#xD;
&#xD;
        Non-inclusion criteria:&#xD;
&#xD;
          -  HLA-DRB1*04-03/06 polymorphisms; recent hospitalization (&lt;1 month); food supplement&#xD;
             based on antioxidant; medicated in fibrate/telmisartan (modulator of PPARs)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Policlinic of Oxford (IPOCA)</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011 Aug 5;11(9):607-15. doi: 10.1038/nri3041.</citation>
    <PMID>21818123</PMID>
  </reference>
  <reference>
    <citation>Mothe-Satney I, Murdaca J, Sibille B, Rousseau AS, Squillace R, Le Menn G, Rekima A, Larbret F, Pele J, Verhasselt V, Grimaldi PA, Neels JG. A role for Peroxisome Proliferator-Activated Receptor Beta in T cell development. Sci Rep. 2016 Sep 29;6:34317. doi: 10.1038/srep34317.</citation>
    <PMID>27680392</PMID>
  </reference>
  <reference>
    <citation>Rousseau AS, Sibille B, Murdaca J, Mothe-Satney I, Grimaldi PA, Neels JG. alpha-Lipoic acid up-regulates expression of peroxisome proliferator-activated receptor beta in skeletal muscle: involvement of the JNK signaling pathway. FASEB J. 2016 Mar;30(3):1287-99. doi: 10.1096/fj.15-280453. Epub 2015 Dec 9.</citation>
    <PMID>26655383</PMID>
  </reference>
  <reference>
    <citation>Le Garf S, Murdaca J, Mothe-Satney I, Sibille B, Le Menn G, Chinetti G, Neels JG, Rousseau AS. Complementary Immunometabolic Effects of Exercise and PPARbeta/delta Agonist in the Context of Diet-Induced Weight Loss in Obese Female Mice. Int J Mol Sci. 2019 Oct 19;20(20):5182. doi: 10.3390/ijms20205182.</citation>
    <PMID>31635041</PMID>
  </reference>
  <reference>
    <citation>Namazi N, Larijani B, Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials. Clin Nutr. 2018 Apr;37(2):419-428. doi: 10.1016/j.clnu.2017.06.002. Epub 2017 Jun 8.</citation>
    <PMID>28629898</PMID>
  </reference>
  <reference>
    <citation>Cui J, Huang D, Zheng Y. Ameliorative effects of alpha-lipoic acid on high-fat diet-induced oxidative stress and glucose uptake impairment of T cells. Free Radic Res. 2016 Oct;50(10):1106-1115. doi: 10.1080/10715762.2016.1210140. Epub 2016 Aug 4.</citation>
    <PMID>27383289</PMID>
  </reference>
  <reference>
    <citation>Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, Sandouk A, Hesse C, Castro CN, Bahre H, Tschirner SK, Gorinski N, Gohmert M, Mayer CT, Huehn J, Ponimaskin E, Abraham WR, Muller R, Lochner M, Sparwasser T. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med. 2014 Nov;20(11):1327-33. doi: 10.1038/nm.3704. Epub 2014 Oct 5. Erratum In: Nat Med. 2015 Apr;21(4):414.</citation>
    <PMID>25282359</PMID>
  </reference>
  <reference>
    <citation>Kempkes RWM, Joosten I, Koenen HJPM, He X. Metabolic Pathways Involved in Regulatory T Cell Functionality. Front Immunol. 2019 Dec 3;10:2839. doi: 10.3389/fimmu.2019.02839. eCollection 2019.</citation>
    <PMID>31849995</PMID>
  </reference>
  <reference>
    <citation>Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol. 2016 May 19;17(6):618-25. doi: 10.1038/ni.3466.</citation>
    <PMID>27196520</PMID>
  </reference>
  <reference>
    <citation>Zou J, Lai B, Zheng M, Chen Q, Jiang S, Song A, Huang Z, Shi P, Tu X, Wang D, Lu L, Lin Z, Gao X. CD4+ T cells memorize obesity and promote weight regain. Cell Mol Immunol. 2018 Jun;15(6):630-639. doi: 10.1038/cmi.2017.36. Epub 2017 Jun 19.</citation>
    <PMID>28626237</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>June 11, 2020</study_first_submitted>
  <study_first_submitted_qc>June 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut Polyclinique de Cannes (IPOCA)</investigator_affiliation>
    <investigator_full_name>Fauqué</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <keyword>Regulatory T cells</keyword>
  <keyword>Immunometabolic</keyword>
  <keyword>Alpha lipoic acid</keyword>
  <keyword>Physical activity</keyword>
  <keyword>Non-drug strategy</keyword>
  <keyword>Obesity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thioctic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04436419
org study id: 3573-I
nct id: NCT04436419
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
Forty women aged between 18 and 75 years-old with a BMI> 30kg/m2 are recruited to participate
      in the evaluation of their medical management. They participate in an 8-week protocol as part
      of hospital medical treatment for weight loss at the Oxford Polyclinic in Cannes (IPOCA). The
      effects of 2 independent variables will be studied: (1) an adapted physical activity program
      and (2) nutritional supplementation with R-α-Lipoic acid (2x300mg/d) versus placebo
      (double-blind). The volunteers are randomly assigned to the different groups: Placebo with or
      without exercise groups and ALA with or without exercise groups. At the start of the protocol
      (T0), at 4 weeks (T4) and at 8 weeks (T8), various measurements are carried out (physical
      capacities, nutritional status, body composition, distribution of adipose mass by CT-scan). A
      venous sample taken for all participants is done at T0, T4 and T8 to investigate the immune
      profile of circulating T lymphocytes.

      This project is part of a translational research project to assess current care and to
      investigate the immunometabolic effects of a non-drug medical care of obesity (adapted
      physical activities, nutritional supplementation with α-lipoic acid, quality of food intake).
Obesity-related inflammation is central to the development of type 2 diabetes and potentiated
      by advancing age, inactive behavior and sedentary lifestyle. Metabolism and immunity are
      entangled in their respective effects: the pathways of inflammation are involved in
      metabolism and the metabolic state plays a predominant role in immune function. Physical
      activity and calorie restriction are first-line, non-drug strategies recommended in reducing
      obesity and insulin resistance and then prevent type 2 diabetes. However, the impact of their
      combined effects on circulating immune cells or those residing in adipose tissue and skeletal
      muscle, remains insufficiently understood to allow a nutritional prescription (i.e., quality
      of nutritional intake and efficient doses of physical activity) favorable to preventive
      medical care, individualized, and effective. If the risk associated with an increase in
      visceral fat mass is linked to a change in the pro/anti-inflammatory status, it is essential
      to reduce this risk by acting on its cause, regardless of the weight loss. In a context of
      low-grade inflammation, these effects could lead to an anti-inflammatory profile of T cells,
      specifically regulatory T cells (Treg) whose metabolism is extremely "flexible" at the
      periphery and into visceral adipose tissue (directly involved in inflammation of obesity).

      ALA (Alpha-Lipoic Acid) is known to play a pivotal role in cellular redox status and energy
      metabolism by modulating inflammatory and metabolic signaling pathways such as those of
      NF-kB, JNK, PI3K/Akt, p38 MAPK, AMPK or PPARβ/δ. As ALA is a possible metabolic modulator, it
      would affect the metabolism of T cells. And therefore ALA could be a complementary measure to
      non-drug strategies by potentiating the correction of the inflammatory state linked to
      obesity.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Prevention
masking: Triple (Participant, Care Provider, Investigator)
measure: Variation in the prevalence of regulatory T cells from Peripheral Blood Mononuclear Cells (PBMCs) drawn from whole blood at the beginning (T0), mid-course (T4) and the end of the course (T8).
time frame: Through study completion, an average of 2 months
description: Cells were gently washed twice and resuspended in PBS. Stained cell preparations were analyzed using a BD FACS Canto II flow cytometer. The staining and gating strategy were used for traited human PBMCs by utilizing CD3+, CD4+, CD25+ and FoxP3+ antibodies. We have discriminated CD3+CD4+ versus CD3+CD4-. Finally, at this stage CD25+FoxP3+ (Regulatory T cells) cells were gated as part of the CD3+CD4+ population.
measure: 60% increasing in PPARβ/δ expression, estimated from the level of expression of its main target gene CPT1a, in human PBMC between the beginning (T0) and end of the course (T8).
time frame: Through study completion, an average of 2 months
description: Total mRNA was extracted with Trizol reagent and the relative amount of CPT1a mRNA was calculated using the comparative ΔΔCT method after quantitative RT-PCR analysis.
measure: Improvement of Redox status by measuring GSH/GSSH ratio in human whole blood between the beginning (T0) and end of the course (T8).
time frame: Through study completion, an average of 3 months
description: The GSH/GSSG Assay is designed to accurately measure total, reduced and oxidized glutathione in biological samples using an enzymatic method that utilizes Ellman's Reagent (DTNB) and glutathione reductase (GR).
measure: Reduction of the area from visceral adipose tissue measured by computed-tomography scan between the beginning (T0) and end of the course (T8).
time frame: Through study completion, an average of 1 months
description: A computed-tomography scan (CT-scan) which allowed to discriminate the area of subcutaneous adipose tissue from visceral fatty area (VFA) was calculated from x-ray performed at the third lumbar level. Visceral abdominal adipose tissue was estimated by subtracting total abdominal and subcutaneous adipose tissues areas.
arm group label: Placebo
arm group type: Placebo Comparator
description: Patients benefited from a complete hospitalization including dietary monitoring (food intake was controlled in order to provide 30% less of their estimated daily energy expenditure) with a personalized food plan and an adapted physical activity program (5 sessions per week supervised by a graduated health physical activity coach), plus placebo administration (2x per day) apart from meal.
arm group label: ALA
arm group type: Active Comparator
description: Patients benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program, plus R-ALA enantiomer administration (2x300mg per day) apart from meal.
intervention type: Dietary Supplement
intervention name: Alpha lipoic acid (plus full hospitalization)
description: Women are included in an 8-weeks randomized double-blind against placebo supplementation study with ALA (eight per group) according to the following criteria:
Inclusion criteria: BMI> 30; aged between 18 and 75 years. Non-inclusion criteria: HLA-DRB1*04-03/06 polymorphisms; recent hospitalization (<1 month); food supplement based on antioxidant; medicated in fibrate / telmisartan (modulator of PPARs); patients presenting an acute inflammatory state.
Exclusion criteria: Pregnant and/or lactating women; not affiliated with social security; not mutual health insurance; person deprived of liberty; participation in clinical research in the last 6 months.
Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. α-LA (2x300mg/day of R-ALA) was administered double-blinded in the form of 2 capsules apart from meals.
arm group label: ALA
intervention type: Dietary Supplement
intervention name: Placebo (full hospitalization: dietary monitoring with an adapted physical activity program)
description: Women are included in an 8-weeks randomized in placebo group. Patients included in this clinical trial benefited from a complete hospitalization including dietary monitoring with a personalized food plan and an adapted physical activity program. Placebo (2x300mg/day) was administered double-blinded in the form of 2 capsules apart from meals.
arm group label: Placebo
criteria: 
gender: Female
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: No
facility: 
country: France
citation: Gleeson M, Bishop NC, Stensel DJ, Lindley MR, Mastana SS, Nimmo MA. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat Rev Immunol. 2011 Aug 5;11(9):607-15. doi: 10.1038/nri3041.
PMID: 21818123
citation: Mothe-Satney I, Murdaca J, Sibille B, Rousseau AS, Squillace R, Le Menn G, Rekima A, Larbret F, Pele J, Verhasselt V, Grimaldi PA, Neels JG. A role for Peroxisome Proliferator-Activated Receptor Beta in T cell development. Sci Rep. 2016 Sep 29;6:34317. doi: 10.1038/srep34317.
PMID: 27680392
citation: Rousseau AS, Sibille B, Murdaca J, Mothe-Satney I, Grimaldi PA, Neels JG. alpha-Lipoic acid up-regulates expression of peroxisome proliferator-activated receptor beta in skeletal muscle: involvement of the JNK signaling pathway. FASEB J. 2016 Mar;30(3):1287-99. doi: 10.1096/fj.15-280453. Epub 2015 Dec 9.
PMID: 26655383
citation: Le Garf S, Murdaca J, Mothe-Satney I, Sibille B, Le Menn G, Chinetti G, Neels JG, Rousseau AS. Complementary Immunometabolic Effects of Exercise and PPARbeta/delta Agonist in the Context of Diet-Induced Weight Loss in Obese Female Mice. Int J Mol Sci. 2019 Oct 19;20(20):5182. doi: 10.3390/ijms20205182.
PMID: 31635041
citation: Namazi N, Larijani B, Azadbakht L. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials. Clin Nutr. 2018 Apr;37(2):419-428. doi: 10.1016/j.clnu.2017.06.002. Epub 2017 Jun 8.
PMID: 28629898
citation: Cui J, Huang D, Zheng Y. Ameliorative effects of alpha-lipoic acid on high-fat diet-induced oxidative stress and glucose uptake impairment of T cells. Free Radic Res. 2016 Oct;50(10):1106-1115. doi: 10.1080/10715762.2016.1210140. Epub 2016 Aug 4.
PMID: 27383289
citation: Berod L, Friedrich C, Nandan A, Freitag J, Hagemann S, Harmrolfs K, Sandouk A, Hesse C, Castro CN, Bahre H, Tschirner SK, Gorinski N, Gohmert M, Mayer CT, Huehn J, Ponimaskin E, Abraham WR, Muller R, Lochner M, Sparwasser T. De novo fatty acid synthesis controls the fate between regulatory T and T helper 17 cells. Nat Med. 2014 Nov;20(11):1327-33. doi: 10.1038/nm.3704. Epub 2014 Oct 5. Erratum In: Nat Med. 2015 Apr;21(4):414.
PMID: 25282359
citation: Kempkes RWM, Joosten I, Koenen HJPM, He X. Metabolic Pathways Involved in Regulatory T Cell Functionality. Front Immunol. 2019 Dec 3;10:2839. doi: 10.3389/fimmu.2019.02839. eCollection 2019.
PMID: 31849995
citation: Newton R, Priyadharshini B, Turka LA. Immunometabolism of regulatory T cells. Nat Immunol. 2016 May 19;17(6):618-25. doi: 10.1038/ni.3466.
PMID: 27196520
citation: Zou J, Lai B, Zheng M, Chen Q, Jiang S, Song A, Huang Z, Shi P, Tu X, Wang D, Lu L, Lin Z, Gao X. CD4+ T cells memorize obesity and promote weight regain. Cell Mol Immunol. 2018 Jun;15(6):630-639. doi: 10.1038/cmi.2017.36. Epub 2017 Jun 19.
PMID: 28626237
responsible party type: Sponsor-Investigator
investigator affiliation: Institut Polyclinique de Cannes (IPOCA)
investigator full name: Fauqué
investigator title: Doctor
mesh term: Obesity
mesh term: Obesity, Abdominal
mesh term: Thioctic Acid
sharing ipd: Undecided